Literature DB >> 15246947

Cutaneous ulcers with type I cryoglobulinemia treated with plasmapheresis.

A T Vila1, M A Barnadas, J Ballarin, R Garcia, C Juarez, P Madoz, E Ramila, A Alomar.   

Abstract

Severe necrotic cutaneous ulcers and kidney involvement secondary to type I cryoglobulinemia can be a therapeutic challenge. Plasmapheresis has been reported useful to treat autoimmune diseases such as thrombotic thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and Goodpasture's syndrome. We report the case of a patient who presented necrotic lesions with kidney involvement due to type I cryoglobulinemia (Ig G kappa) that evolved to a multiple myeloma. Treatment with high doses of corticosteroid plus cyclophosphamide did not control the disorder. Therapy with plasmapheresis produced a marked decrease in cryoglobulin levels and a subsequent relevant clinical improvement of cutaneous lesions and renal function. In cryoglobulinemia, plasmapheresis can be used as effective adjunt therapy to minimize cutaneous, renal and/or neurologic involvement.

Entities:  

Mesh:

Year:  2004        PMID: 15246947

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  4 in total

1.  Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.

Authors:  Richard J Lin; James J Curran; Todd M Zimmerman; Jie Song; Timothy B Niewold; Nadera J Sweiss
Journal:  J Clin Rheumatol       Date:  2010-03       Impact factor: 3.517

Review 2.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

3.  Leukocytoclastic vasculitis in a patient with type 1 cryoglobulinemia.

Authors:  Paul Y Liu; Pamela E Prete; Gary Kukes
Journal:  Case Rep Rheumatol       Date:  2011-10-10

4.  Cryoglobulinemic vasculitis and glomerulonephritis: concerns in clinical practice.

Authors:  Yi-Pu Chen; Hong Cheng; Hong-Liang Rui; Hong-Rui Dong
Journal:  Chin Med J (Engl)       Date:  2019-07-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.